Search results
Results from the WOW.Com Content Network
Ginkgo Bioworks (NYSE: DNA) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst ...
Bioengineering specialist Ginkgo Bioworks Holdings (NYSE: DNA) delivered some badly needed good news for investors on Tuesday. Those folks commensurately rewarded the company by trading up its ...
News. Science & Tech. Shopping. Sports. Weather. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. ... Ginkgo isn't a stock I would suggest putting in your portfolio ...
News. Science & Tech. Shopping. Sports. Weather. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. ... Ginkgo Bioworks (NYSE: DNA) stock has had a rough 12 months ...
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology .
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $2.78, marking a +0.72% move from the previous day.
This page was last edited on 28 January 2022, at 18:59 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Can this struggling stock turn things around? For premium support please call: 800-290-4726 more ways to reach us